Study of Efficacy and Safety of Voretigene Neparvovec in Japanese Patients With Biallelic RPE65 Mutation-associated Retinal Dystrophy
Clinical trial NCT04516369 · COMPLETED
Trial details
- NCT number
- NCT04516369
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-11-24
- Primary completion
- 2022-04-05
- Enrollment
- 4
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.